昌红科技(300151) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 273,494,647.13, representing a 51.57% increase compared to CNY 180,436,427.16 in the same period last year[9] - Net profit attributable to shareholders was CNY 39,558,308.51, a significant increase of 125.34% from CNY 17,554,778.59 year-on-year[9] - The net profit after deducting non-recurring gains and losses reached CNY 36,572,204.92, up 228.52% from CNY 11,132,461.52 in the previous year[9] - Basic and diluted earnings per share were both CNY 0.08, doubling from CNY 0.04 year-on-year[9] - The company's operating revenue for the reporting period reached RMB 273,494,647.13, representing a year-on-year increase of 51.57% due to significant growth in medical business sales[25] - The net profit attributable to shareholders was RMB 39,558,300, reflecting a year-on-year growth of 125.34%[30] - The total profit for the current period was ¥48,192,510.45, compared to ¥20,809,929.70 in the previous period, reflecting a growth of 131.9%[74] - The operating profit for the current period was ¥48,843,276.56, compared to ¥21,771,649.31 in the previous period, marking an increase of 124.5%[74] Cash Flow - The net cash flow from operating activities was CNY 41,719,444.69, a turnaround from a negative cash flow of CNY -8,084,926.48 in the same period last year[9] - The cash flow from operating activities showed a net increase of RMB 41,719,444.69, a significant improvement compared to a negative cash flow of RMB -8,084,926.48 in the previous period, marking a 616.02% change[29] - Operating cash inflow totaled approximately ¥329.5 million, an increase from ¥205.1 million in the previous period, reflecting a growth of 60.5%[86] - Operating cash outflow amounted to ¥287.8 million, compared to ¥213.2 million previously, resulting in a net cash flow from operating activities of ¥41.7 million, a significant improvement from a negative cash flow of ¥8.1 million last year[86] - The company reported a cash inflow from operating activities of ¥312,827,133.33, compared to ¥194,954,240.27 in the previous period[82] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,361,997,930.98, a 2.40% increase from CNY 1,330,099,588.54 at the end of the previous year[9] - The company's total assets increased by 127.25% in non-current assets, primarily due to prepayments for land transfer fees and equipment purchases[24] - The company's total assets amounted to CNY 1,361,997,930.98, an increase from CNY 1,330,099,588.54 at the end of the previous period[49] - The total current liabilities increased to CNY 247,701,705.98 from CNY 243,201,598.53, indicating a rise of about 1.0%[52] - Total liabilities decreased to ¥141,837,532.37 from ¥158,833,633.50, a decline of 10.7%[62] Shareholder Information - The top shareholder, Li Huanchang, holds 42.24% of the shares, totaling 212,258,000 shares, with a portion pledged[13][16] - The company has not engaged in any repurchase transactions among its top shareholders during the reporting period[21] Expenses - The company's sales expenses surged by 262.45% to RMB 14,477,754.06, driven by increased promotional and transportation costs[25] - Research and development expenses rose by 40.20% to RMB 10,980,222.66, attributed to increased project activities in the subsidiary[25] - R&D expenses for Q1 2021 were ¥10,980,222.66, up from ¥7,831,567.09, indicating a 40.1% increase in investment in innovation[67] Government Support - The company reported a government subsidy of CNY 3,614,487.54 during the reporting period[9] Strategic Initiatives - The company aims to strengthen risk management and operational efficiency while focusing on technological innovation and cost reduction strategies[30] - The company plans to invest in a high polymer medical consumables industrial park in the Hangzhou Bay Shangyu Economic and Technological Development Zone[35] Compliance and Governance - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[39] - The company has no violations regarding external guarantees during the reporting period[40] - The company has not engaged in any research, communication, or interview activities during the reporting period[42]